Detalles de la búsqueda
1.
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.
Ann Oncol;
35(6): 549-558, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38423389
2.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Ann Oncol;
34(8): 660-669, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37201751
3.
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Ann Oncol;
34(6): 531-542, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062416
4.
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer.
Breast Cancer Res Treat;
188(2): 351-359, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33788134
5.
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trialâ.
Ann Oncol;
31(10): 1350-1358, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32634611
6.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Breast Cancer Res Treat;
175(2): 389-399, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30796651
7.
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.
Ann Oncol;
29(1): 186-192, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29045642
8.
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Ann Oncol;
28(11): 2768-2772, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28945833
9.
Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772].
Ann Oncol;
33(3): 355, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35012798
10.
Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
Breast Cancer Res Treat;
155(1): 109-15, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26643086
11.
[Breast cancer. Individualized therapy concepts]. / Mammakarzinom. Individualisierte Therapiekonzepte.
Internist (Berl);
54(2): 194-9, 2013 Feb.
Artículo
en Alemán
| MEDLINE | ID: mdl-23371261
12.
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry.
ESMO Open;
8(3): 101213, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37075697
13.
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer.
ESMO Open;
7(5): 100561, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36084395
14.
Reply to the letter to the editor 'Insertion of central venous catheters (CVCs): any changes in the past ten years' by Biffi et al.
Ann Oncol;
27(7): 1351-2, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27037295
15.
Central venous access in oncology: ESMO Clinical Practice Guidelines.
Ann Oncol;
26 Suppl 5: v152-68, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26314776
16.
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Breast;
50: 11-18, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31958661
17.
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
Eur J Cancer;
96: 82-90, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29679775
18.
ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07.â11.â2015.
Geburtshilfe Frauenheilkd;
76(2): 156-163, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26941448
19.
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Curr Med Res Opin;
32(7): 1217-24, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26971372
20.
Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Breast;
24(1): 24-31, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25543874